Biocon Biologics and Civica Join Forces to Revolutionize Insulin Access in the US

Biocon Biologics Ltd, a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has announced a groundbreaking collaboration with Civica, Inc. to expand access to affordable Insulin Aspart in the United States. Under this strategic agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, who will produce and commercialize the final product at their Virginia facility. This partnership aims to address the critical need for affordable insulin among the 38.4 million Americans living with diabetes. The collaboration complements Biocon Biologics' own Insulin Aspart product currently under FDA review, reinforcing the company's commitment to improving diabetes care accessibility in the US market.

 

Sources: Biocon Limited, PR Newswire, Financial Express